• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Why TD SYNNEX Shares Are Trading Lower By Over 5%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session

    9/26/23 12:56:35 PM ET
    $ACON
    $ACST
    $ADPT
    $AFIB
    Medical Specialities
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ACON alert in real time by email

    Gainers

    Soleno Therapeutics, Inc. (NASDAQ:SLNO) shares jumped 318.5% to $18.54 after the company released top-line results from randomized withdrawal period of study C602 of DCCR for Prader-Willi Syndrome.

    Femasys Inc. (NASDAQ:FEMY) surged 244% to $1.1410 after the company received FDA 510(k) clearance for FemaSeed, an infertility treatment designed to deliver sperm directly to where conception occurs in a woman's fallopian tube.

    Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) shares gained 77.3% to $18.50. Alfasigma agreed to acquire Intercept Pharmaceuticals for $19.00 per share in cash.

    Immunovant, Inc. (NASDAQ:IMVT) jumped 75.6% to $35.60 after the company announced initial IMVT-1402 Phase 1 SAD and 300 mg subcutaneous MAD results.

    Tharimmune Inc (NASDAQ:THAR) shares gained 39.5% to $0.3090 after falling around 5% on Monday.

    Acasti Pharma Inc. (NASDAQ:ACST) gained 27.1% to $2.2250. Acasti announced a $7.5 million private placement equity financing.

    Cano Health, Inc. (NYSE:CANO) surged 24.2% to $0.3380. Cano Health said it sold substantially all of the assets associated with the operation of Cano Health's senior-focused primary care centers in Texas and Nevada to CenterWell Senior Primary Care.

    Bullfrog AI Holdings, Inc. (NASDAQ:BFRG) gained 23.6% to $3.5499. Bullfrog AI announced data from its preclinical study investigating the anti-cancer activity of a novel prodrug of mebendazole for glioblastoma.

    Avalo Therapeutics, Inc. (NASDAQ:AVTX) gained 21.9% to $0.1987 after jumping over 36% on Monday. Avalo Therapeutics reported the payoff of the remainder of its $35 million debt owed to Horizon Technology Finance.

    Adaptive Biotechnologies Corporation (NASDAQ:ADPT) shares climbed 21.2% to $6.16. Adaptive recently announced the launch of Epic integration for clonoSEQ.

    Infobird Co., Ltd (NASDAQ:IFBD) shares gained 19.7% to $0.1561. Infobird recently announced receipt of delinquency notification letter from the Nasdaq.

    ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) gained 18.8% to $4.28 after Director Rajeev Shah acquired a total of 2,700,000 shares an average price of $3.03 for roughly $8.18 million.

    Roivant Sciences Ltd. (NASDAQ:ROIV) gained 17% to $11.94 after the company announced initial IMVT-1402 Phase 1 SAD and 300 mg subcutaneous MAD results.

    Verve Therapeutics, Inc. (NASDAQ:VERV) rose 16.6% to $13.25. Verve Therapeutics to unveil interim data on VERVE-101 at the American Heart Association's Event.

    Pliant Therapeutics, Inc. (NASDAQ:PLRX) gained 15% to $16.77 after the company announced bexotegrast met its primary and secondary endpoints in the Phase 2a liver fibrosis trial.

    Fisker Inc. (NYSE:FSR) rose 14.2% to $6.06 after the company announced that deliveries are set to ramp up.

    Planet Green Holdings Corp. (NYSE:PLAG) surged 14.1% to $0.6470.

    BYND Cannasoft Enterprises Inc. (NASDAQ:BCAN) rose 13.2% to $1.01.

    Adaptive Biotechnologies Corporation (NASDAQ:ADPT) gained 12.4% to $5.71.

    Acutus Medical, Inc. (NASDAQ:AFIB) jumped 11.7% to $0.6601.

    Aclarion, Inc. (NASDAQ:ACON) gained 11.4% to $0.39.

    Vera Therapeutics, Inc. (NASDAQ:VERA) climbed 10.3% to $15.69 as HC Wainwright & Co maintained a Buy rating on the stock and raised its price target from $10 to $25.

    Blue Star Foods Corp. (NASDAQ:BSFC) rose 8.6% to $0.2520 after dipping 20% on Monday.

    NightHawk Biosciences, Inc. (NASDAQ:NHWK) gained 7.5% to $0.57.

    Precigen, Inc. (NASDAQ:PGEN) rose 7.4% to $1.44.

    Losers

    TransCode Therapeutics, Inc. (NASDAQ:RNAZ) shares fell 68.7% to $0.7990 after the company priced its $8 million public offering of 15.7 million shares at $0.51 per share.

    Murphy Canyon Acquisition Corp. (NASDAQ:CDT) fell 35.7% to $6.67 after dipping 38% on Monday.

    Davis Commodities Limited (NASDAQ:DTCK) declined 33.2% to $3.15. The company recently priced its IPO at $4 per share.

    Molekule Group, Inc. (NASDAQ:MKUL) fell 28.8% to $0.2064.

    Polished.com Inc. (NYSE:POL) fell 25.2% to $0.0928 after surging 40% on Monday.

    United Natural Foods, Inc. (NYSE:UNFI) fell 23.3% to $14.51 after the company reported mixed fourth-quarter financial results and issued guidance.

    MicroAlgo Inc. (NASDAQ:MLGO) fell 19.2% to $2.43.

    Genetron Holdings Limited (NASDAQ:GTH) fell 18.2% to $0.7201.

    Greenfire Resources Ltd. (NYSE:GFR) declined 16.4% to $6.52.

    Novo Integrated Sciences, Inc. (NASDAQ:NVOS) fell 14.9% to $0.2261.

    Ebix, Inc. (NASDAQ:EBIX) dipped 12.8% to $10.36.

    New Pacific Metals Corp. (NYSE:NEWP) declined 12.2% to $1.9487. New Pacific Metals announced CAD$35 million bought deal financing.

    Greenfire Resources Ltd. (NYSE:GFR) fell 11.5% to $6.90.

    Biophytis S.A. (NASDAQ:BPTS) fell 11.2% to $1.4099. Biophytis shares jumped over 72% on Monday after the company and Skyepharma announced a partnership agreement for the production of regulatory batches of Sarconeos (BIO101) for severe forms of Covid-19.

    Roadzen, Inc. (NASDAQ:RDZN) fell 10.3% to $4.8135.

    Akili, Inc. (NASDAQ:AKLI) declined 9.4% to $0.5130.

    FaZe Holdings Inc. (NASDAQ:FAZE) shares fell 8.9% to $0.1749 after jumping 25% on Monday.

    MSP Recovery, Inc. (NASDAQ:LIFW) shares fell 7.8% to $0.1867 after declining around 15% on Monday.

    TROOPS, Inc. (NASDAQ:TROO) fell 6.4% to $3.8199.

    Sacks Parente Golf, Inc. (NASDAQ:SPGC) fell 6.3% to $1.2750. The company recently posted a narrower second-quarter loss.

    TD SYNNEX Corporation (NYSE:SNX) fell 5.2% to $96.64. TD Synnex reported a third-quarter revenue decline of 9.1% Y/Y to $13.96 billion, missing the consensus of $14.11 billion.

    Now Read This: Ethereum Rises But Remains Below This Key Level; Maker Emerges As Top Gainer

    Get the next $ACON alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ACON
    $ACST
    $ADPT
    $AFIB

    CompanyDatePrice TargetRatingAnalyst
    Avalo Therapeutics Inc.
    $AVTX
    2/2/2026$50.00Buy
    Guggenheim
    TD SYNNEX Corporation
    $SNX
    1/13/2026$180.00Buy
    Goldman
    United Natural Foods Inc.
    $UNFI
    1/8/2026Hold
    Deutsche Bank
    Immunovant Inc.
    $IMVT
    1/6/2026$50.00Peer Perform → Outperform
    Wolfe Research
    Avalo Therapeutics Inc.
    $AVTX
    12/18/2025$39.00Outperform
    Mizuho
    New Pacific Metals Corp.
    $NEWP
    12/5/2025Outperform
    BMO Capital Markets
    Adaptive Biotechnologies Corporation
    $ADPT
    12/2/2025$21.00Equal-Weight
    Morgan Stanley
    Femasys Inc.
    $FEMY
    11/20/2025$6.50Buy
    Laidlaw
    More analyst ratings

    $ACON
    $ACST
    $ADPT
    $AFIB
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Femasys Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    ATLANTA, Feb. 27, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ:FEMY), a leading biomedical innovator making fertility and non-surgical permanent birth control more accessible and cost-effective to women worldwide, announced today it has granted to two new non-executive employees who began their employment with Femasys in February 2026 options to purchase 185,000 shares of Femasys common stock. These inducement grants were granted at an exercise price per share of $0.50 and $0.57, equal to the closing price of Femasys common stock on the date of employment as reported by Nasdaq. This grant was approved by the Compensation Committee of Femasys' Board of Directors and made as an inducement

    2/27/26 5:26:33 PM ET
    $FEMY
    Medical/Dental Instruments
    Health Care

    Femasys Announces FemBloc® Permanent Birth Control Has Achieved MDSAP Certification, Advancing Global Market Access

    -- FemBloc becomes the latest Femasys product to achieve MDSAP certification, building on a proven track record of compliance -- ATLANTA, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ:FEMY), a leading biomedical innovator making fertility and non-surgical permanent birth control more accessible and cost-effective to women worldwide, announced today that its FemBloc permanent birth control system has achieved certification under the Medical Device Single Audit Program (MDSAP). The MDSAP certification positions the Company to accelerate regulatory and commercial execution across key global markets, including the United States, Canada, Japan, Australia, and Brazil. In the U.S., FDA

    2/26/26 9:00:00 AM ET
    $FEMY
    Medical/Dental Instruments
    Health Care

    Soleno Therapeutics Announces Retirement of James Mackaness and Appointment of Jennifer Fulk as Chief Financial Officer

    REDWOOD CITY, Calif., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ:SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced the appointment of Jennifer Fulk as Chief Financial Officer, succeeding James Mackaness, who announced that he will be retiring from the Company by the end of the first quarter. Mr. Mackaness will serve as a consultant to Soleno through the end of the year to ensure a smooth transition. Mrs. Fulk brings to Soleno more than two decades of public company experience in leading financial strategy, investor relations, financial reporting, and operational efficiency, with a diverse c

    2/26/26 8:00:00 AM ET
    $SLNO
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $ACON
    $ACST
    $ADPT
    $AFIB
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for OCALIVA issued to INTERCEPT PHARMS INC

    Submission status for INTERCEPT PHARMS INC's drug OCALIVA (SUPPL-8) with active ingredient OBETICHOLIC ACID has changed to 'Approval' on 02/24/2022. Application Category: NDA, Application Number: 207999, Application Classification: Labeling

    2/25/22 4:36:46 AM ET
    $ICPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for OCALIVA issued to INTERCEPT PHARMS INC

    Submission status for INTERCEPT PHARMS INC's drug OCALIVA (SUPPL-7) with active ingredient OBETICHOLIC ACID has changed to 'Approval' on 05/26/2021. Application Category: NDA, Application Number: 207999, Application Classification: Labeling

    5/27/21 5:23:24 AM ET
    $ICPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    March 5, 2021 - Coronavirus (COVID-19) Update: FDA Authorizes Adaptive Biotechnologies T-Detect COVID Test

    For Immediate Release: March 05, 2021 Today, the U.S. Food and Drug Administration issued an emergency use authorization (EUA) for the T-Detect COVID Test developed by Adaptive Biotechnologies. The T-Detect COVID Test is a next generation sequencing based (NGS) test to aid in identifying individuals with an adaptive T cell immune response to SARS-CoV-2, indicating recent or prior infection with SARS-CoV-2.  “Today’s authorization further und

    3/5/21 10:37:33 PM ET
    $ADPT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ACON
    $ACST
    $ADPT
    $AFIB
    SEC Filings

    View All

    SEC Form S-8 filed by Adaptive Biotechnologies Corporation

    S-8 - Adaptive Biotechnologies Corp (0001478320) (Filer)

    2/27/26 5:05:19 PM ET
    $ADPT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 10-K filed by Vera Therapeutics Inc.

    10-K - Vera Therapeutics, Inc. (0001831828) (Filer)

    2/26/26 5:25:11 PM ET
    $VERA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-K filed by Adaptive Biotechnologies Corporation

    10-K - Adaptive Biotechnologies Corp (0001478320) (Filer)

    2/26/26 4:31:07 PM ET
    $ADPT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ACON
    $ACST
    $ADPT
    $AFIB
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Pappas James C bought $573,000 worth of shares (17,000 units at $33.71) (SEC Form 4)

    4 - UNITED NATURAL FOODS INC (0001020859) (Issuer)

    1/6/26 8:21:40 AM ET
    $UNFI
    Food Distributors
    Consumer Discretionary

    Director Enright Patrick G bought $249,985 worth of shares (5,882 units at $42.50) (SEC Form 4)

    4 - Vera Therapeutics, Inc. (0001831828) (Issuer)

    12/15/25 8:07:34 PM ET
    $VERA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Roivant Sciences Ltd. bought $349,999,986 worth of shares (16,666,666 units at $21.00), increasing direct ownership by 17% to 113,317,007 units (SEC Form 4)

    4 - Immunovant, Inc. (0001764013) (Issuer)

    12/12/25 5:17:21 PM ET
    $IMVT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ACON
    $ACST
    $ADPT
    $AFIB
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Operating Officer Gloria Melanie sold $90,184 worth of shares (3,238 units at $27.85), decreasing direct ownership by 2% to 170,273 units (SEC Form 4)

    4 - Immunovant, Inc. (0001764013) (Issuer)

    2/27/26 4:07:42 PM ET
    $IMVT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chief Medical Officer Brenner Robert sold $90,307 worth of shares (2,151 units at $41.98), decreasing direct ownership by 4% to 50,947 units (SEC Form 4)

    4 - Vera Therapeutics, Inc. (0001831828) (Issuer)

    2/25/26 8:01:07 PM ET
    $VERA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SVP, FINANCE, CHIEF ACCT OFFCR Young Joseph R sold $130,864 worth of shares (3,117 units at $41.98), decreasing direct ownership by 5% to 64,722 units (SEC Form 4)

    4 - Vera Therapeutics, Inc. (0001831828) (Issuer)

    2/25/26 8:00:18 PM ET
    $VERA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACON
    $ACST
    $ADPT
    $AFIB
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Guggenheim initiated coverage on Avalo Therapeutics with a new price target

    Guggenheim initiated coverage of Avalo Therapeutics with a rating of Buy and set a new price target of $50.00

    2/2/26 6:51:00 AM ET
    $AVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Goldman resumed coverage on TD Synnex with a new price target

    Goldman resumed coverage of TD Synnex with a rating of Buy and set a new price target of $180.00

    1/13/26 9:18:14 AM ET
    $SNX
    Retail: Computer Software & Peripheral Equipment
    Technology

    Deutsche Bank initiated coverage on United Natural Foods

    Deutsche Bank initiated coverage of United Natural Foods with a rating of Hold

    1/8/26 10:59:33 AM ET
    $UNFI
    Food Distributors
    Consumer Discretionary

    $ACON
    $ACST
    $ADPT
    $AFIB
    Leadership Updates

    Live Leadership Updates

    View All

    Soleno Therapeutics Announces Retirement of James Mackaness and Appointment of Jennifer Fulk as Chief Financial Officer

    REDWOOD CITY, Calif., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ:SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced the appointment of Jennifer Fulk as Chief Financial Officer, succeeding James Mackaness, who announced that he will be retiring from the Company by the end of the first quarter. Mr. Mackaness will serve as a consultant to Soleno through the end of the year to ensure a smooth transition. Mrs. Fulk brings to Soleno more than two decades of public company experience in leading financial strategy, investor relations, financial reporting, and operational efficiency, with a diverse c

    2/26/26 8:00:00 AM ET
    $SLNO
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Tharimmune, Inc. Appoints Mark Wendland Chairman of the Board and Names Angela Radkowski Chief Operating Officer

    Leadership Expansion Supports Execution of Canton Network Infrastructure Strategy Former DRW and Citadel Leader Joins as COO to Drive Institutional Platform Expansion NEW YORK, Feb. 6, 2026 /PRNewswire/ -- Tharimmune, Inc. (NASDAQ:THAR) ("Tharimmune" or the "Company"), the first publicly traded company to leverage Canton Coin ("CC") to support the Canton Network's ability to digitize traditional financial markets, today announced that its Board of Directors (the "Board") has elected Mark Wendland, Chief Executive Officer, as Chairman of the Board and approved the appointment of Angela Radkowski as Chief Operating Officer, effective February 5, 2026. Mr. Wendland succeeds Vincent LoPriore, wh

    2/6/26 8:15:00 AM ET
    $THAR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Tharimmune Elects Jill Sommers and William Wiley to Board of Directors

    New Directors Strengthen Governance as Company Advances Canton Network Infrastructure Former CFTC Commissioner Jill Sommers Brings Decades of Regulatory and Public Policy Experience DRW Chief of Staff William Wiley, CFA, Adds Extensive Leadership Experience Across Capital Markets and Global Operations NEW YORK, Feb. 2, 2026 /PRNewswire/ -- Tharimmune, Inc. (NASDAQ:THAR) ("Tharimmune" or the "Company"), the first publicly traded company to leverage Canton Coin ("CC") to support the Canton Network's ability to digitize traditional financial markets, today announced that its Board of Directors (the "Board") has elected Jill Sommers and William Wiley, CFA, to the Board, effective February 1, 20

    2/2/26 8:15:00 AM ET
    $THAR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACON
    $ACST
    $ADPT
    $AFIB
    Financials

    Live finance-specific insights

    View All

    Soleno Therapeutics Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Update on U.S. Launch of VYKAT™ XR

    REDWOOD CITY, Calif., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ:SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today reported financial results for the fourth quarter and full-year ended December 31, 2025 and provided an update on the U.S. launch of VYKAT™ XR (diazoxide choline) extended-release tablets. Fourth Quarter and Full-Year 2025 and Recent Corporate Highlights Revenue, net, from the sale of VYKAT XR for the three and twelve months ended December 31, 2025, was $91.7 million and $190.4 million, respectively.From approval on March 26, 2025 through December 31, 2025, Soleno reports: 1,250 patien

    2/25/26 4:01:00 PM ET
    $SLNO
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    ARS Pharmaceuticals Announces Conference Call and Webcast for its Fourth Quarter and Full Year 2025 Financial Results and Participation at Upcoming Conferences

    SAN DIEGO, Feb. 23, 2026 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (NASDAQ:SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect patients from allergic reactions that could lead to anaphylaxis, today announced the company will host a conference call and webcast on Monday, March 9, 2026 at 5:30 a.m. PT / 8:30 a.m. ET to discuss its fourth quarter and full year 2025 financial results and business highlights. Dial-in information for conference participants may be obtained by registering for the event. In addition, ARS Pharma Management will be participating at several upcoming investor conferences: 10th Annual Oppenheimer Emer

    2/23/26 8:00:00 AM ET
    $SPRY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CDT Acquires Strategic Stake in Sarborg to Transform its AI-Driven Asset Strategy

    NAPLES, Fla. and CAMBRIDGE, United Kingdom, Feb. 20, 2026 (GLOBE NEWSWIRE) -- CDT Equity Inc. (NASDAQ:CDT) ("CDT" or the "Company"), today announced that it has entered into a strategic transaction to acquire a 20% equity stake in Sarborg Limited ("Sarborg"), an agentic AI signature intelligence business operating across multiple industrial sectors. The investment formalizes and deepens the existing collaboration between CDT and Sarborg, which has already supported the evaluation of CDT's clinical assets through Sarborg's proprietary signature analysis and artificial intelligence capabilities. Sarborg's business is built on the principle that biological, chemical and industrial signatures

    2/20/26 8:30:00 AM ET
    $CDT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACON
    $ACST
    $ADPT
    $AFIB
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by MSP Recovery Inc.

    SC 13D/A - MSP Recovery, Inc. (0001802450) (Subject)

    12/17/24 4:05:04 PM ET
    $LIFW
    EDP Services
    Technology

    Amendment: SEC Form SC 13D/A filed by Acutus Medical Inc.

    SC 13D/A - Acutus Medical, Inc. (0001522860) (Subject)

    12/16/24 9:52:56 PM ET
    $AFIB
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form SC 13D filed by Davis Commodities Limited

    SC 13D - DAVIS COMMODITIES Ltd (0001949478) (Subject)

    12/10/24 8:00:12 AM ET
    $DTCK
    Farming/Seeds/Milling
    Industrials